Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the
Annual Report for 2015 now is available at the company’s website:
www.medivir.com.
– Medivir continued to build long-term value in 2015 via a R&D portfolio based
on our established and proven technology platform. One of the most important of
these steps was the completion, according to plan, of safety testing in our MIV
-711 osteoarthritis project, followed, at the end of the year, by the approval
to start a phase II trial on osteoarthritis patients. We have a good starting
point, with highly competent employees and a number of promising projects in
development, and our strong financial position affords us the potential to
conduct long-term projects and to complement our portfolio with new projects,
said Medivir’s CEO, Niklas Prager, in his CEO’s Statement in this year’s Annual
Report.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.
About Medivir
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
